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ABSTRACT
Cancer biomarkers that can define disease status and provide a prognostic insight 
are essential for the effective management of patients with breast cancer (BC).
The prevalence, clinicopathological and prognostic significance of PRPF38B 
expression in a consecutive series of 1650 patients with primary invasive breast 
carcinoma were examined using immunohistochemistry. Furthermore, the 
relationship(s) between clinical outcome and PRPF38B expression was explored in 
627 patients with ER-negative (oestrogen receptor) disease, and 322 patients with 
HER2-overexpressing disease.
Membranous expression of PRPF38B was observed in 148/1388 (10.7%) cases and 
was significantly associated with aggressive clinicopathological features, including high 
grade, high mitotic index, pleomorphism, invasive ductal carcinoma of no specific type 
(IDC-NST), ER-negative, HER2-overexpression and p53 mutational status (all p < 0.01).  
In patients with ER-negative disease receiving chemotherapy, nuclear expression of 
PRPF38B was significantly associated with a reduced risk of relapse (p = 0.0004), 
whereas membranous PRPF38B expression was significantly associated with increased 
risk of relapse (p = 0.004; respectively) at a 5 year follow-up. When patients were 
stratified according to ER-negative/HER2-positive status, membranous PRPF38B 
expression was associated with a higher risk of relapse in those patients that did not 
receive trastuzumab therapy (p = 0.02), whereas in those patients with ER-negative/
HER2-positive disease that received trastuzumab adjuvant therapy, membranous 
PRPF38B expression associated with a lower risk of relapse (p = 0.00018).
Nuclear expression of PRPF38B is a good prognostic indicator in both ER-
negative patients and ER-negative/HER2-positive BC (breast cancer) patients, 
whereas membranous localisation of PRPF38B is a poor prognostic biomarker that 
predicts survival benefit from trastuzumab therapy in patients with ER-negative/
HER2-overexpressing BC.
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INTRODUCTION
The incidence of breast cancer in the UK has 
grown by 50% in the past 25 years, making it the UK’s 
most common form of cancer. In 2010, 49,564 women 
were diagnosed with breast cancer and 11,684 women 
died from the disease in 2011. Although the number of 
diagnosed cases has increased, so has the 5 year survival 
rate for patients, with almost 85.1% of women surviving 
5 years following first diagnosis (www.cancerresearchuk.
org). However, despite such increases in the survival rates 
of women with breast cancer, recurrence occurs in over 
20% of patients, as a consequence of which there is an 
unmet clinical need to identify biomarkers that can stratify 
patients at the risk of recurrence and identify those patients 
who optimally respond to therapy [1].
The promotion of cell growth and proliferation 
contributes to the development and progression of breast 
cancer. Growth signalling pathways are triggered by a 
number of membrane bound and intracellular receptors, 
including the oestrogen receptor, progesterone receptor 
(PR) and the epidermal growth factor receptor HER2. The 
expression and biological activities of membrane-bound 
receptors therefore play a significant role in the initiation 
and progression of breast cancer, and the prevention, 
treatment and relapse of the disease [2]. HER2 belongs 
to the family of epidermal growth factor receptors, the 
amplification or overexpression of which occurs in 20–25% 
of human breast cancers [3]. The amplification of 
HER2 strongly correlates with carcinogenesis and is an 
independent predictor for the poor prognosis of patients 
with breast cancer [4–6]. HER2 overexpression is also 
found at metastatic sites, thereby suggesting that therapies 
targeting HER2 may be effective for both localised and 
metastatic disease [7]. This is significant given that 
approximately 90% of cancer-related deaths are due to 
aggressive, metastatic disease. To date, four therapies have 
been approved for the targeting of HER2-positive breast 
cancer: two antibodies (trastuzumab and pertuzumab), an 
antibody-drug conjugate (ado-trastuzumab emtansine), 
and a small molecule kinase inhibitor (lapatinib) [8].
Trastuzumab (Herceptin®) was the first candidate 
drug which was registered for use in patients with breast 
cancer overexpressing HER2. Although trastuzumab 
prolongs the survival of HER2-positive breast cancer 
patients and is the standard of care for HER2-positive 
breast cancer (NCCN Clinical Practice Guidelines in 
Oncology Breast Cancer (2012) V. 2), resistance to 
the drug is common, with the overall response rates 
(ORRs) with single-agent trastuzumab being in the 
range of 15–26% [9, 10]. Substantially higher response 
rates (~50%) have been achieved when trastuzumab 
is used in combination with standard chemotherapy 
[11]. Trastuzumab is associated with significant drug 
acquisition costs [12] and side-effects that include infusion 
reactions, as well as cardiac and pulmonary toxicity [7]. 
Given the resistance to therapy, costs and side-effects, 
the ability to stratify patients on the basis of their clinical 
responsiveness to trastuzumab therapy would have a 
significant beneficial impact on the clinical management 
of patients with HER2-positive breast cancer. With this in 
mind, the development of an improved understanding of 
the fundamental mechanisms of trastuzumab action and 
molecular determinants of response, and the identification 
of therapeutic agents that can either potentiate the effect of 
trastuzumab or target cells which have become resistant to 
trastuzumab have become a major focus for the treatment 
of HER2-positive breast cancer.
As part of an ongoing programme to identify 
novel cancer testis antigens that may be associated with 
cancer, we employed the SEREX (serological analysis of 
recombinant cDNA expression libraries) methodology 
to screen cancer patient sera against a normal testicular 
cDNA library (unpublished results). This screen identified 
a promising candidate, PRPF38B [GenBank: NP_060531], 
which belongs to a family of genes that are related to the 
pre-mRNA splicing factor from yeast and is commonly 
perceived as being located within the nucleus of cells. [13].
The current study investigated the clinicopathological 
significance of the expression of PRPF38B in a consecutive 
series of normal breast tissue (n = 40), primary invasive 
breast carcinomas (n = 1650) and ER-negative disease 
(n = 627). Furthermore, the relationship between 
the expression of PRPF38B and clinical outcome 
of patients with HER2-positive disease who did not 
(n = 221) or did (n = 101) receive trastuzumab has been 
explored in consecutive cases of a HER2-positive cohort 
(total n = 322) in order to examine a potential association 
between PRPF38B protein expression and aggressive 
disease/therapeutic response following trastuzumab 
treatment.
Our findings suggest that determining the 
localisation of PRPF38B expression in patients with ER-
negative and ER-negative/HER2-positive breast cancer 
has the potential to stratify these patients for therapy. 
To the best of our knowledge, this is the first study to 
report on the prognostic and potential predictive value of 
PRPF38B expression in primary breast cancer.
RESULTS
Tissue expression of PRPF38B and its 
association with clinicopathological features  
and relevant breast cancer biomarkers
In all of the normal tissues examined, PRPF38B 
was predominately located within the nucleus of cells 
with some weak cytoplasmic, but no membranous 
staining (Figure 1A). Out of 1650 cases of early stage 
invasive breast cancer, 1388 were suitable for the scoring 
of PRPF38B expression. Eight hundred and ninety tissues 
(64%) showed no staining for PRPF38B, whereas 148 
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tissues (10.7%) showed membranous staining and 360 
(25.9%) displayed nuclear staining (Figure 1B–1D). 
Simultaneous expression of both nuclear and membranous 
was rarely observed (10/1388; 0.7%).
The analysis of 1388 tissue cores that were 
randomised into 2 approximately equal populations (training 
and test sets) revealed no significant differences between the 
2 populations regarding expression of PRPF38B and other 
clinicopathological features (Supplementary Table 1).
PRPF38B nuclear staining was statistically associated 
with the expression of oestrogen and progesterone 
receptors, but with a lack of HER2 expression. In contrast, 
membranous PRPF38B staining was associated with 
aggressive phenotypes including ER-negative, PR-negative, 
HER-overexpression, high pleomorphism and high tumour 
grade. Furthermore, membranous PRPF38B expression 
was significantly associated with the expression of markers 
that are linked with high proliferation including high 
mitotic index, high Ki67, p53 mutation and low Bcl2. The 
summary of these staining patterns relative to these and 
other clinicopathological correlates is provided in Table 1.
Relationship between membranous PRPF38B 
expression and clinical outcome of early stage 
primary invasive breast cancer
Whereas positive nuclear staining was associated 
with disease-free survival (DFS, data not shown), high 
membranous expression of PRPF38B was significantly 
associated with increased risk of relapse ( p = 0.004) at 
10 years (Figure 2).
Multivariate Cox regression analysis including 
validated prognostic factors (lymph node metastases, 
histological grade, tumour size, ER receptor positivity 
and HER2 status) and controlling for both endocrine and 
chemotherapies, demonstrated that membranous PRPF38B 
expression was an independent predictor of DFS (training 
set; HR (hazard ratio) [95% CI (confidence interval)): 1.76 
(1.04–2.98, p = 0.037 and test set: [HR (95% CI): 1.69 
(1.00–2.85, p = 0.048)]. Pooling both the training data set 
and test set together, membranous PRPF38B expression 
was associated with a 65% increase in the risk of relapse 
[HR (95% CI): 1.65 (1.14–2.38, p = 0.0007)] (Table 2).
Relationship between cellular localisation of 
PRPF38B expression and clinical outcome for 
patients with ER-negative breast cancer
Out of 693 cases of ER-negative breast cancer, 627 
cases were suitable for the scoring of PRPF38B expression; 
202 (32.2%) showed no staining, 132 (21.9%) demonstrated 
membranous expression, 285 (45.5%) showed nuclear 
expression and 27 (4.3%) showed cytoplasmic expression. 
Positive nuclear expression of PRPF38B was associated 
with reduced risk of relapse at the 5 year follow-up [HR 
(95% CI) = 0.64 (0.48–0.86); p = 0.002], whereas positive 
membranous PRPF38B expression was associated with 
increased risk of relapse at the 5-year follow-up [HR (95% 
CI) = 1.47 (1.07–2.01; p = 0.017] (Figure 3A). Stratification 
of patients according to chemotherapy treatment revealed 
that patients with ER-negative disease with positive nuclear 
PRPF38B expression who received cyclophosphamide, 
Figure 1: PRPF38B protein expression in breast tissues. Representative photomicrographs of PRPF38B expression, as assessed 
using IHC. (A) PRPF38B demonstrated homogenously intense nuclear staining in normal breast tissue. (B) PRPF38B expression was 
localised in the nucleus of peripheral cells and tumour epithelial cells exhibited membranous staining in ductal carcinoma in situ. (C) High 
grade invasive breast cancer demonstrated staining of PRPF38B in the cytoplasm and nucleus of cells, with intense membranous staining 
also being observed [magnification 200× for A–C]. (D) Enlarged image of (C) demonstrating intense membranous staining.
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Table 1: Clinicopathological characteristics of non-membranous (N-MB) or membranous (MB) PRPF38B 
Variables
Training Set (n = 688)
n (%) p value
Test Set (n = 688)
n (%) p value
N-MB (n = 613) MB (n = 75) N-MB (n = 616) MB (n = 72)
Pathological parameters
Tumour size 
T1 a + b (≤1.0)
T1 c (>1.0–2.0)
T2 (>2.0–5.0) 
T3 (>5)
60 (9.9)
319 (52.7)
213 (35.2)
13 (2.1)
4 (5.5)
37 (50.7)
31 (42.5)
1 (1.4)
0.465
76 (12.8)
296 (48.1)
223 (36.3)
17 (2.8)
5 (7.0)
34 (47.9)
30 (42.3)
2 (2.8)
0.499
Lymph node stage 
Negative
Positive (1–3 nodes)
Positive (>3 nodes)
382 (62.8)
175 (28.8)
51 (8.4)
38 (51.4)
28 (37.8)
8 (10.8)
0.159
367 (59.7)
197 (32.0)
51 (8.3)
43 (60.6)
15 (21.1)
13 (18.3)
0.010
Tumour grade
G1 
G2 
G3
110 (18.2)
218 (36.0)
277 (45.8)
4 (5.5)
13 (17.8)
56 (76.7)
<0.0001*
115 (18.7)
213 (34.6)
287 (46.7)
2 (2.8)
16 (22.5)
53 (74.6)
<0.0001*
Mitotic index
M1 (low; mitoses <10)
M2 (medium; mitoses 10–18)
M3 (high; mitoses >18)
246 (40.9)
114 (18.9)
242 (40.2)
6 (8.2)
16 (21.9)
51 (69.9)
<0.0001*
229 (37.4)
112 (18.3)
271 (44.3)
10 (14.1)
11 (15.5)
50 (70.4)
<0.0001*
Pleomorphism
P1
P2
P3
12 (2.0)
257 (42.7)
333 (55.3)
2 (2.7)
14 (19.2)
57 (78.1)
0.001*
20 (3.3)
251 (41.1)
340 (55.6)
0 (0)
13 (18.3)
58 (81.7)
<0.0001*
Tubule formation
T1
T2
T3
31 (5.1)
210 (34.9)
361 (60)
0 (0)
15 (20.5)
58 (79.5)
0.003*
47 (7.7)
209 (34.2)
356 (58.2)
2 (2.8)
14 (19.7)
55 (77.5)
0.006*
Tumour type
IDC-NST
Medullary/atypical
Tubular carcinoma
Invasive lobular carcinoma
Others
301 (55.9)
14 (2.6)
121 (22.4)
61 (11.3)
41 (7.6)
57 (93.4)
1 (1.6)
0 (0)
3 (4.9)
<0.0001*
297 (55.8)
11 (2.1)
122 (22.9)
54 (10.2)
48 (9.0)
53 (84.1)
3 (4.8)
6 (9.5)
1 (1.6)
0 (0)
<0.0001*
Hormonal receptors
Oestrogen receptor 
Negative 
Positive
131 (21.8)
471 (78.2)
47 (65.3)
25 (34.7)
<0.0001* 141 (23.3)
465 (76.7)
39 (56.5)
30 (43.5)
<0.0001*
Progesterone receptor
Negative 
Positive
217 (38.3)
349 (61.7)
54 (76.1)
17 (23.9)
<0.0001* 218 (37.8)
359 (62.2)
43 (66.2)
22 (33.8)
<0.0001*
HER2
Negative 
Overexpression
555 (92.2)
47 (7.8)
32 (43.2)
42 (56.8)
<0.0001* 569 (94.2)
35 (5.8)
36 (50.7)
35 (49.3)
<0.0001*
Cell cycle/apoptosis
P53
Negative 
Positive
406 (82.4)
87 (17.6)
42 (67.7)
20 (32.3)
0.006* 411 (82.0)
90 (18.0)
30 (48.4)
32 (51.6)
<0.0001*
Bcl2
Negative
Positive
179 (32.5)
371 (67.5)
41 (59.4)
28 (40.6)
<0.0001* 169 (30.6)
384 (69.4)
38 (56.7)
29 (43.3)
<0.0001*
Significant differential distributions between non-membranous (N-MB) and membranous (MB) PRPF38B expression. Membranous PPF38B expression 
was more prevalent in Grade 3 tumours, invasive ductal carcinoma–no specific type IDC-NST, patients with ER-negative, PR-negative, HER2-
positive and Bcl2-negative breast cancers. The frequency of membranous expression was associated with a high mitotic index, a marked variation in 
pleomorphism and high tubule formation. No significant differential distribution between membranous and non-membranous PRPF38B expression 
was observed for tumour size and lymph node stage. *Statistically significant differences between the frequency of distribution were calculated using 
Pearson’s Chi-squared analysis with a p value < 0.05 considered statistically significant.
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methotrexate, 5-fluorouracil (CMF) and anthracycline 
chemotherapy were at lower risk of relapse compared to 
those negative for nuclear PRPF38B expression [HR (95% 
CI) = 0.49 (0.33–0.74); p = 0.0004] (Figure 3B(i)). In 
contrast, patients with ER-negative tumours with positive 
membranous PRPF38B expression who received CMF and 
anthracycline chemotherapy had a higher risk of relapse 
compared with patients having membranous PRPF38B 
negative tumours [HR (95% CI) = 2.24 (1.40–3.57); 
p = 0.001] (Figure 3B(ii)).
Relationship between cellular localisation of 
PRPF38B expression and clinical outcome for 
patients with HER2-overexpression
For patients with HER2 over-expressing breast 
cancer who did not receive trastuzumab, the risk of relapse 
was greater for patients with membranous PRPF38B 
positive disease than those with membranous PRPF38B 
negative disease [HR (95% CI) = 1.65 (1.07–2.53); 
p = 0.02] (Figure 4A(i)). In patients with HER2 
Figure 2: Relationship between cellular PRPF38B expression and survival of patients with breast cancer. Membranous 
PRPF38B expression was significantly associated with poor breast cancer specific survival (BCSS) (log rank = 18.06, p = 0.00002) (A) 
and disease-free survival (DFS) in patients with breast cancer (log rank = 8.31, p = 0.004) (B), as calculated using Kaplan-Meier univariate 
survival analysis.
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overexpressing breast cancer that received trastuzumab, 
there was no significant difference in 5 year disease-free 
survival (DFS) between those with positive and negative 
PRPF38B membranous expression [HR (95% CI) = 1.75 
(1.7–2.5); p = 0.49] (Figure 4A(ii)). These findings infer 
that although negative membranous PRPF38B expression 
had no value in predicting the influence of trastuzumab 
therapy on disease-free survival, membranous PRPF38B 
expression did identify a cohort of patients with HER2 
over-expressing disease that benefitted from trastuzumab 
therapy (5 year follow-up) [HR (95% CI) = 0.21 
(0.08–0.52); p = 0.00018] (Figure 4(B)).
DISCUSSION
We have used the SEREX approach to identify 
cancer testis antigens associated with human cancer by 
screening pooled human cancer sera against a human testis 
cDNA expression library. This approach has identified 
a novel splice variant of a previously characterised 
protein called PRPF38B (Supplementary Figure 1) 
which appears to elicit specific immune responses in 
the tumour-bearing host and which, at the RNA level, 
is significantly overexpressed in a significant number of 
breast cancer tissues when compared to their matched 
normal counterparts. In addition, isoforms of this protein 
have been detected in various breast cancer lines and 
its localisation can be observed within the nuclear, 
cytoplasmic and membranous regions (Supplementary 
Figure 2). RT-PCR screening of a panel of normal tissues 
and tissues obtained from patients with different cancers 
suggest that levels of PRPF38B are low in the majority 
of essential organs and that elevated levels of this 
transcript (above the mean + 2 standard deviations) can be 
observed in 5/10 patients with kidney cancer, 2/2 patients 
with gastric cancer, 4/10 patients with prostate cancer 
and 5/10 individuals with benign prostatic hyperplasia 
(Supplementary Figure 3). PRPF38B is a unique 
component of the U4/U6.U5 tri small nuclear ribonuclear 
protein (snRNP) particle and is necessary for an essential 
step in late spliceosome maturation. Lee et al. (2003) 
reported on the isolation of a partial sequence of this gene 
(known as NY-SAR-27) following an immunomic analysis 
of human sarcoma. For this, sera from patients with 
sarcoma were used to screen a testis cDNA library and 
positive clones were identified and sequenced. To the best 
of our knowledge, no further work on this gene has been 
published [13]. Our subsequent detection of PRPF38B in 
a SEREX screen of sera from patients with breast cancer 
and the demonstration that it is over-expressed in breast 
cancer tissue led us to evaluate PRPF38B expression as 
a prognostic and therapeutic outcome predictor in a large 
series of breast cancers.
HER2 positivity is associated with early relapse 
after initial surgery for patients with breast cancer 
and a reduction in survival of up to 50%. Currently, 
anthracycline based chemotherapy in combination with 
trastuzumab is the standard of care for the treatment 
of patients with breast cancer overexpressing HER2. 
However, around 50% and 60% of these tumours are 
resistant to treatment with anthracycline chemotherapy 
and trastuzumab respectively. Furthermore, both drugs 
Table 2: Multivariate Cox regression analysis showing 5 year disease-free survival (DFS) in the training set, test set 
and all patients set
Variables
Training Set Test Set All Patients
HR CI 95% p HR CI 95% p HR CI 95% p
PRPF38B membranous (+) 1.76 1.04–2.98 0.037* 1.69 1.00–2.85 0.048* 1.65 1.14–2.38 0.0007*
PRPF38B membranous (−) 0.82 0.53–1.27 0.38 0.86 0.55–1.35 0.519 0.85 0.62–1.16 0.294
Lymph node metastases (+) 2.22 1.55–3.16 <0.0001* 1.76 1.22–2.54 <0.0001* 1.99 1.54–2.57 <0.0001*
Histological grade (G1/2 
vs 3) 1.47 0.96–2.23 0.074 1.26 1.64–4.00 <0.0001
* 1.91 1.41–2.58 <0.0001*
Size (continuous) 1.23 1.00–1.50 0.05* 1.42 1.19–1.70 <0.0001* 1.35 1.18–1.54 <0.0001*
ER (+) 0.67 0.45–1.02 0.059 0.90 0.59–1.38 0.624 0.77 0.57–1.03 0.078
HER2 (+) 1.22 0.75–1.97 0.42 1.05 0.66–1.66 0.837 0.6 0.81–1.57 0.463
Chemotherapy 0.53 0.30–0.93 0.026* .077 0.49–1.22 0.27 0.58 0.40–85 0.005*
Endocrine therapy 0.47 0.29–76 0.002* 0.60 0.35–1.03 0.065 0.62 0.45–86 0.004*
*Statistical significance was calculated using multivariate Cox regression analysis ( p < 0.05 was considered significant). 
Other validated traditional prognostic factors and cofounders were included in the model, and the model was controlled for 
endocrine and chemotherapy. HR; hazard ratio, CI; confidence interval, ER; oestrogen receptor.
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are associated with a small but significant risk of 
cardiotoxicity. The costs associated with these treatments 
places significant pressure on health service providers 
and a low-cost test which can identify those patients who 
will not respond to trastuzumab therapy would therefore 
provide significant benefits to patients, physicians and 
healthcare providers.
The clinically significant findings of this study are 
that: (1) Membranous PRPF38B expression is significantly 
associated with increased risk of relapse. (2) Membranous 
PRPF38B expression, lymph node stage, histological 
grade, tumour size, ER receptor positivity and Bcl2 status 
are powerful independent predictors for disease-free 
survival. (3) In the ER-negative patient cohort, nuclear 
localisation of PRPF38B was associated with a reduced 
risk of relapse at 5 years, whereas those patients exhibiting 
membranous PRPF38B expression had an increased risk 
of relapse. (4) In patients with ER-negative/HER2-positive 
disease, membranous PRPF38B expression was associated 
with poor prognosis in patients that did not receive 
trastuzumab therapy, but was capable of identifying 
patients with ER-negative/HER2-positive disease that 
responded to trastuzumab therapy. Why membranous 
expression of PRPF38B is associated with an increased 
risk of relapse in patients with HER2+/ER-negative 
disease who did not receive trastuzumab, but is associated 
with a better disease-free survival in those patients treated 
with trastuzumab remains unknown. However, it could 
be that membranous PRPF38B expression is a surrogate 
biomarker for highly proliferative tumours.
Early studies have demonstrated that the relative 
concentrations of specific splicing factors can become 
Figure 3: Relationships between nuclear and membranous PRPF38B expression and clinical outcome in patients with 
ER-negative breast cancer and patients with ER-negative breast cancer who have received chemotherapy rather than 
trastuzumab. [A(i)] Positive nuclear PRPF38B expression was associated with reduced risk of relapse [HR (95% CI) = 0.64 (0.48–0.86); 
p = 0.002]. [A(ii)] Positive membranous PRPF38B expression was associated with increased risk of relapse [HR (95% CI) = 1.47 
(1.07–2.01; p = 0.017]. Stratification of patients according to chemotherapy treatment revealed that [B(i)] ER-negative patients who showed 
positive nuclear PRPF38B expression were at lower risk of relapse compared to those negative for nuclear PRPF38B expression [HR (95% 
CI) = 0.49 (0.33–0.74); p = 0.0004]. [B(ii)] Patients with ER-negative tumours exhibiting positive membranous PRPF38B expression had a 
higher risk of relapse compared with patients with PRPF38B negative tumours [HR (95% CI) = 2.24 (1.40–3.57); p = 0.001]. Disease-free 
survival was assessed over a 5 year period. Relationships were determined using Kaplan-Meier univariate survival analysis.
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altered during early pre-neoplasia and these become more 
pronounced during tumour formation [14]. A recent study 
has identified a set of pre-mRNA splicing factors that are 
required for sister chromatid cohesion in human cells and 
that loss of cohesion was an early cellular consequence 
of compromised splicing. Some cancers were shown to 
harbour mutations in these splicing factors [15].
The ability of PRPF38B expression to predict 
responsiveness to trastuzumab may be related to one 
of the postulated mechanisms of action of trastuzumab. 
However, it is also possible that membranous PRPF38B 
is simply a prognostic biomarker for responsiveness to 
trastuzumab therapy in the ER-negative/HER2-positive 
cohort of patients, rather than its presence having a direct 
influence on the actions of trastuzumab. Identifying the 
potential interactions between PRPF38B and HER2 is 
therefore important for future studies.
Although many (hundreds) of putative biomarkers 
have been proposed to date, these studies lack evidence 
of applicability to a clinical question. To date, the most 
widely investigated tumour tissue biomarkers are UPA/
PAI-1 [16], ki67 [17], the serum biomarkers CA 15-3 
and carcinoembryonic antigen [18] and gene expression 
profiles such as Oncotype DX [16, 19]. Other established 
biomarkers include p53 [20], HER2/neu [21] and BRCA1/
BRCA2 [22]. We have previously published on the 
Figure 4: Relationships between PRPF38B expression and cellular localisation and clinical outcome in patients 
with ER-negative/HER2-positive breast cancer in the presence or absence of trastuzumab treatment. [A(i)] Positive 
membranous PRPF38B expression was associated with an increased risk of relapse in patients that were ER-negative and overexpressing 
HER2 who did not receive trastuzumab, as compared to patients with breast cancer that was negative for membranous PRPF38B expression 
[HR (95% CI) = 1.65 (1.07–2.53); p = 0.02]. [A(ii)] There was no significant difference in the survival of patients with ER-negative/HER2 
overexpressing tumours that were treated with trastuzumab when stratified according to the localisation of PRPF38B [HR (95% CI) = 1.65 
(1.07–2.53); p = 0.49]. [B(i)] Non-membranous expression of PRPF38B was not associated with responsiveness to trastuzumab therapy in 
patients with ER-negative/HER2-positive breast cancer (p = 0.126). [B(ii)] Membranous PRPF38B expression is significantly associated 
with better disease-free survival (DFS) in patients with ER-negative/HER2-positive breast cancer who are treated with trastuzumab (p = 
0.00018). Disease-free survival was assessed over a 5 year period. Relationships were determined using Kaplan-Meier univariate survival 
analysis.
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identification of multiple breast cancer biomarkers [23, 24] 
and work on these includes their utility as potential vaccine 
candidates [25–27] and as a prognostic biomarker and 
chemotherapy sensitivity predictor in breast cancer [28]. 
Although the plethora of breast cancer biomarkers is 
steadily increasing, we believe we are the first to report on 
a biomarker that can aid clinicians in their decision-making 
process regarding the administration of trastuzumab therapy 
to ER-negative/Her2-positive breast cancer patients.
The identification of PRPF38B as a potential 
biomarker for predicting patient response to trastuzumab 
therapy aligns this biomarker well for use alongside other 
commercially available tests. Although Oncotype DX 
is one such available platform, this is a genomic-based 
approach and is not utilised in ER-negative patients, nor as 
a means for predicting a patient’s response to trastuzumab. 
An immunohistochemistry based approach, performed on 
tumour material that is resected at the point of surgical 
intervention, could be undertaken at the same time as 
staining for other clinically-relevant markers (i.e. Her2/
neu status). If PRPF38B was included in this biomarker 
panel then the results would aid the clinical decision-
making process with regards to potentially avoiding the 
administration of costly trastuzumab that would be of 
no clinical benefit to the patient, but which may cause 
significant unwanted side-effects.
In terms of the potential economic costs and 
benefits associated with the addition of this biomarker test 
into clinical practice, it is known that about 60 patients 
per million population per year present with HER2-
positive breast cancer and these are routinely treated with 
trastuzumab (some indication as to the prevalence of 
PRPF38B alone and in combination with ERBB2 (Her2) 
is given in Supplementary Table 2). However, of these 
patients, less than 50% will respond and this represents 
a significant over-treatment of patients, costing the NHS 
£73 million (US$124 million) for trastuzumab alone. In 
terms of patient benefit, the use of this proposed biomarker 
as a predictive test will avoid a large number of patients 
undergoing unnecessary treatments which are disruptive 
to their lives and may result in unnecessary toxicity, 
with adverse consequences on their quality of life. In 
essence, the identification of this model has the potential 
to underpin a new, precision medicine-based approach 
for treating this form of breast cancer which will enable 
these patients to be treated with more effective strategies, 
thereby improving outcomes and quality of life.
In the wider context, the significance of membranous 
PRPF38B as a biomarker for response to trastuzumab 
therapy may not be solely restricted to breast cancer. HER2 
overexpression has been described in a variety of tumours 
including, but not limited to, bladder, breast, cervix, 
colorectal, endometrium, oesophagus, gastric, head and 
neck, liver, melanoma, lung (NSCLC), osteosarcoma, ovary, 
prostate and salivary duct [8]. Trastuzumab is approved 
for the treatment of breast, gastric and gastroesophageal 
junction cancer by the US Federal Drugs Administration 
(FDA), and there are mounting anecdotal reports of 
responses to HER2-targeted agents in patients with NSCLC 
[29–33] and cancer of the salivary duct [34–38].
Finally, the membranous expression of PRPF38B 
may have a potential utility as an immunotherapeutic 
target. Numerous studies have emphasised the variable 
clinical benefits of HER2-targeted therapies [21, 39, 40], 
and there is a significant emphasis on developing new 
immunomodulatory drugs and HER2-targeted therapies 
that can be used to augment responses and clinical 
outcome in combination [39]. The identification of 
membranous PRPF38B expression in breast cancer affords 
the opportunity to develop an antibody targeting strategy 
for therapeutic intervention.
CONCLUSIONS
This study demonstrates that the expression of 
PRPF38B is an independent prognostic marker in breast 
cancer. Nuclear PRPF38B expression was significantly 
associated with a decreased risk of relapse at 5 years in 
patients with ER-negative disease and patients with ER-
negative disease that had received chemotherapy, rather 
than trastuzumab. Furthermore, membranous expression 
of PRPF38B was significantly associated with a poor 
prognosis at the 5 year follow-up in patients with ER-
negative/HER2-positive breast cancer who were treated 
prior to 2006 and did not receive trastuzumab therapy. After 
2006, patients with ER-negative/HER2-positive breast 
cancer were treated with trastuzumab and, in these patients, 
membranous expression of PRPF38B in the primary cancer 
was significantly associated with better disease-free survival 
(DFS) at the 5 year follow-up. This study therefore reveals 
and highlights the potential importance of membranous 
PRPF38B expression as a parameter for predicting 
therapeutic response to trastuzumab therapy in patients with 
ER-negative/HER2-positive breast cancer.
These findings suggest that further validation in 
larger, independent cohorts of patients with ER negative/
HER2-positive breast cancer is warranted. These will need 
to focus on evaluating the value of membranous PRPF38B 
expression as a tool for stratifying patients for trastuzumab 
therapy rather than other HER2 targeting strategies. 
Exploring the utility of this biomarker as an indicator of 
response to trastuzumab therapy in other cancer types, for 
which trastuzumab is currently approved as a therapeutic 
option, is also indicated.
PATIENTS AND METHODS
Expression of PRPF38B in early stage primary 
invasive breast cancer and normal breast tissue
The expression of PRPF38B in tissues from a 
consecutive series of 1650 patients with primary invasive 
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breast carcinomas who were diagnosed between 1986 
and 1999, and entered into the Nottingham Tenovus 
Primary Breast Carcinoma series was determined using 
immunohistochemistry; 1388 cores within the TMAs 
were suitable for immunohistochemical (IHC) staining 
and assessment. Patients were randomised into two equal 
cohorts using a double random number sort, for which 
alternate cases were allocated into a training set and a test 
set. Both cohorts contained a similar proportion of patients 
with regards to clinicopathological features, treatment and 
survival data (Supplementary Tables 1 and 3).
Prior to 1989, patients received standard surgery 
(mastectomy or wide local excision) with radiotherapy, 
after which patients received adjuvant therapy on the 
basis of prognostic and predictive parameters, as indicated 
using the Nottingham Prognostic Index (NPI), ERα and 
menopausal status. However, patients within the ‘good’ 
NPI group (≤3.4) did not receive adjuvant therapy. 
Hormone therapy (HT) was prescribed to post-menopausal 
patients with ERα positive and NPI scores >3.4 (moderate 
and poor prognostic group), whereas ERα negative patients 
received classical cyclophosphamide, methotrexate, 
5-flouracil (CMF) chemotherapy. Pre-menopausal 
patients within the moderate and poor prognostic groups 
were candidates for CMF chemotherapy, and patients 
with ERα positive tumours were also offered hormone 
therapy. Median follow-up was 111 months (range 1 to 
233 months).
PRPF38B protein expression was also evaluated in 
40 normal breast tissue biopsy specimens removed from 
women (age range 25-60 years) with no family history 
of breast cancer that underwent reduction mammoplasty, 
primarily due to cosmetic reasons.
PRPF38B expression in ER-negative breast 
cancer
To evaluate the relationship between PRPF38B 
expression and clinical outcome after receiving adjuvant 
chemotherapy, we analysed its expression in a consecutive 
series of 693 patients with early stage ER-negative 
breast cancer who had been diagnosed and managed at 
Nottingham City Hospital between 1999 and 2007. This 
series included 303 patients treated before 2000 who were 
either chemotherapy-naïve or received adjuvant CMF, and 
390 patients who were treated after 2000 and were either 
chemotherapy-naïve or were treated with anthracycline-
based adjuvant chemotherapy (anthracycline-ACT). 
Disease-free survival was used as a primary endpoint.
PRPF38B expression in HER2-overexpressing 
breast cancer
To evaluate the relationship between PRPF38B 
expression and clinical outcome in HER2-positive breast 
cancer, we analysed its expression in a consecutive series of 
443 patients with early stage breast cancer over-expressing 
HER2 who had been diagnosed and managed at Nottingham 
City Hospital between 1986 and 2010. This series included 
303 patients who were chemotherapy-naïve or received 
adjuvant CMF before 2006, and 140 patients who were 
treated after 2006 and received trastuzumab therapy. 
Disease-free survival was used as a primary endpoint.
The Reporting Recommendations for Tumor Marker 
Prognostic Studies (REMARK) criteria were adhered 
to throughout this study. All work was approved by the 
Nottingham Research Ethics Committee (approval number 
C1080301).
Tissue microarrays (TMAs) and 
immunohistochemistry (IHC)
Breast tumour TMAs were constructed using 6 
replicate 0.6 mm cores from the centre and periphery 
of the tumours of each patient. The TMAs were 
immunohistochemically profiled for the expression 
of PRPF38B and other clinically significant markers, 
as described previously [41]. The primary antibodies, 
clone, source, optimal dilution and scoring system used 
are summarised in Supplementary Table 4. TMAs were 
subjected to microwave antigen retrieval in 0.01 M pH 
6.0 citrate buffer prior to an overnight incubation at 
room temperature with a monospecific rabbit antibody to 
PRPF38B (1:1000) which was raised against the 17 amino 
acid sequence IEQESQEKQHKNKDETV conjugated to 
KLH (custom prepared by Pacific Immunology, USA). Two 
rabbits received 4 immunisations, and 4 production bleeds 
from each animal were pooled and antibody affinity purified 
using custom affinity columns against the synthesised 
peptide. The specificity of the monospecific PRPF38B 
antibody was confirmed by demonstrating that specific 
PRPF38B IHC staining and the presence of bands in 
immunoblots were completely abrogated by pre-incubating 
the antibody with the relevant peptide, but not with an 
irrelevant peptide (data not shown). Immunohistochemical 
staining was performed using a Novolink detection 
kit according to the manufacturer’s protocol (Leica 
Microsystems, UK) on a DakoCytomation Techmate 500 
Plus (DakoCytomation,UK) automatic immunostainer.
The expression of HER2, oestrogen and 
progesterone receptors was assessed according to the most 
recent American Society of Clinical Oncology/College 
of American Pathologists (ASCO/CAP) guidelines [42]. 
HER2 status of the tissues that were used in the current 
study was assessed using immunohistochemistry and 
fluorescence in situ hybridisation (FISH), as previously 
described [43]. Positive and negative (omission of the 
primary antibody and IgG-matched serum) controls were 
included in each immunohistochemistry run.
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Evaluation of PRPF38B staining
Tumour cores were evaluated by two pathologists 
who were blinded to the clinicopathological characteristics 
of the patients (co-authors: TAF, IOE). Intra- and 
inter-observer agreements were excellent (k > 0.8; 
Cohen’s k and multirater k-tests, respectively). Whole 
field inspection of the core was scored and intensities 
of nuclear, cytoplasmic and membranous staining were 
grouped as follows: 0 = no staining, 1 = weak staining, 
2 = moderate staining and 3 = strong staining. The 
percentage of each category was estimated.
Survival data and statistics
Data on overall survival, disease-free survival, and 
development of loco-regional and distant metastases (DM) 
were maintained on a prospective basis. DFS was defined 
as the number of months from diagnosis to the occurrence 
of local recurrence, local lymph node (LN) relapse or 
DM relapse. Breast cancer specific survival (BCSS) 
was defined as the number of months from diagnosis to 
the occurrence of breast cancer-related death. Survival 
was censored if the patient was still alive at the time of 
analysis, lost to follow-up, or died from other causes.
Pearson’s Chisquare, Fisher’s exact, Student’s 
t-test and ANOVA oneway tests were performed using 
SPSS 17.0 statistical software (SPSS Inc, USA). 
Cumulative survival probabilities were estimated using 
the Kaplan-Meier method and a log rank test was used 
to assess significant differences between survival rates. 
Multivariate analysis for survival was performed using a 
Cox proportional hazard regression model. Each variable 
was assessed in univariate analysis as a continuous and 
categorical variable, and the two models were compared 
using an appropriate likelihood ratio test. Hazard ratios 
(HR) and 95% confidence intervals (CI) were estimated 
for each variable. All tests were two-sided with a 95% CI 
and a p value < 0.05 was considered to reflect statistical 
significance. For multiple comparisons, p values were 
adjusted according to Holm-Bonferroni method.
Abbreviations
IDCNST (invasive ductal carcinoma of no specific 
type), ER (oestrogen receptor), BC (breast cancer), PR 
(progesterone receptor), ORR (overall response rates), 
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